Cardiac Dimensions Raises $53 Million Series E Financing

心脏尺寸公司完成5300万美元E轮融资

To fund completion of the EMPOWER Trial U.S. pivotal study and continue the commercialization of the Carillon Mitral Contour System

为完成EMPOWER试验的美国关键研究提供资金，并继续推进Carillon Mitral Contour系统的商业化进程

KIRKLAND, Wash., March 20, 2025-- Cardiac Dimensions®, a leader in minimally invasive treatments for heart failure and functional mitral regurgitation (FMR), today announced the close of an oversubscribed $53 million Series E financing round led by Ally Bridge Group with significant participation from existing investors.

华盛顿州柯克兰市，2025年3月20日——Cardiac Dimensions®，作为心力衰竭和功能性二尖瓣反流（FMR）微创治疗领域的领导者，今天宣布完成了由 Ally Bridge Group 领投的超额认购5300万美元的E轮融资，现有投资者也积极参与。

This financing will fund the completion of the EMPOWER Trial U.S. pivotal study and support the continued commercialization of the innovative Carillon Mitral Contour System®..

这笔资金将用于完成EMPOWER试验的美国关键研究，并支持创新的Carillon Mitral Contour System®的持续商业化。

“Cardiac Dimensions is uniquely positioned to provide a safe, simple, and effective solution for heart failure patients suffering from FMR. A financing of this magnitude reflects the strong conviction of Ally Bridge, as well as our existing insiders, in the Carillon® therapy’s ability to play a central role in the treatment of this high-need patient population,” said Rick Wypych, president and CEO of Cardiac Dimensions..

“Cardiac Dimensions拥有独特的优势，能够为患有FMR的心力衰竭患者提供一种安全、简单且有效的解决方案。此次融资的规模反映了Ally Bridge以及我们现有内部人士对Carillon®疗法在治疗这一高需求患者群体中发挥核心作用的坚定信心，”Cardiac Dimensions总裁兼首席执行官Rick Wypych表示。

“With these additional resources, we are also well-positioned to continue our global commercial expansion of the Carillon therapy to improve the lives of patients with this debilitating disease,” continued Wypych.

“有了这些额外的资源，我们也有望继续在全球范围内推广Carillon疗法，从而改善这种衰竭性疾病患者的生活。” Wypych继续说道。

In addition to lead investor Ally Bridge Group, new investor Claret Capital Partners and existing Cardiac Dimensions investors Hostplus, M.H. Carnegie, Horizon 3 Healthcare, Lumira Ventures, and a confidential strategic investor significantly participated in the round.

除了领投的 Ally Bridge Group 之外，新投资者 Claret Capital Partners 和现有投资者 Cardiac Dimensions 的 Hostplus、M.H. Carnegie、Horizon 3 Healthcare、Lumira Ventures 以及一位未公开的战略投资者也积极参与了此轮融资。

“We are excited to lead this financing to help support Cardiac Dimensions’ significant advancements in the treatment of heart failure patients with FMR,” said Steve Plachtyna of Ally Bridge Group and new member of the company’s board of directors. “We have been very impressed with the progress the company has made over the past several years in both their clinical efforts and their expansion of commercial sales outside the U.S.

“我们很高兴主导此次融资，以帮助支持Cardiac Dimensions在治疗心力衰竭伴功能性二尖瓣反流（FMR）患者方面取得的重大进展，”Ally Bridge Group的史蒂夫·普拉赫蒂纳（Steve Plachtyna）以及公司董事会新成员表示。“过去几年中，公司在临床努力和美国以外的商业销售扩展方面取得的进展给我们留下了深刻印象。

This financing will fund and accelerate both of these efforts.”.

这笔资金将为这两项工作提供资金并加速其进展。

The Carillon device is designed to restore natural mitral valve function without damaging the mitral valve leaflets. The simple, catheter-based procedure works by restoring the valve’s natural function and promoting favorable left ventricular remodeling. Clinical studies have shown the Carillon therapy reduces mitral regurgitation, improves quality of life, and has extended survival for a broad range of patients with FMR.

Carillon装置旨在恢复天然二尖瓣功能，同时不损伤二尖瓣叶。这种简单、基于导管的手术通过恢复瓣膜的自然功能并促进左心室的有利重塑来发挥作用。临床研究表明，Carillon疗法可减少二尖瓣反流、提高生活质量，并延长了广大功能性二尖瓣反流（FMR）患者的生存期。

Furthermore, patients with early-stage FMR may be treated with Carillon therapy as a front-line treatment option, as it does not prevent the use of other future therapies..

此外，早期FMR患者可以将Carillon疗法作为一线治疗选择，因为它不会妨碍未来其他疗法的使用。

Functional mitral regurgitation is a prevalent condition among individuals with heart failure, which affects over 64 million people globally.¹ Studies indicate that moderate or greater severity of FMR is present in up to 59% of heart failure patients.² When left untreated, FMR can lead to increased hospitalization due to heart failure, reduced quality of life and higher mortality rates..

功能性二尖瓣反流是心力衰竭患者中普遍存在的状况，全球有超过6400万人受其影响。¹ 研究表明，中度或更严重的功能性二尖瓣反流在心力衰竭患者中的发生率高达59%。² 如果不加以治疗，功能性二尖瓣反流会导致因心力衰竭住院的几率增加、生活质量下降以及死亡率升高。

About Cardiac Dimensions

关于心脏维度

Cardiac Dimensions® is a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and associated cardiovascular conditions. The company’s flagship technology, the Carillon Mitral Contour System®, is designed to address functional mitral regurgitation (FMR) using a catheter-based approach.

Cardiac Dimensions® 是开发创新性、微创治疗模式以应对心力衰竭及相关心血管疾病的领导者。该公司的旗舰技术——Carillon Mitral Contour System®，旨在通过基于导管的方法来解决功能性二尖瓣反流 (FMR)。

Cardiac Dimensions has operations in Kirkland, Washington, Sydney, Australia and Frankfurt, Germany. For more information, visit www.cardiacdimensions.com..

Cardiac Dimensions 在华盛顿州柯克兰、澳大利亚悉尼和德国法兰克福设有业务。欲了解更多信息，请访问 www.cardiacdimensions.com。

Cardiac Dimensions, Carillon, and Carillon Mitral Contour System are registered trademarks of Cardiac Dimensions.

Cardiac Dimensions、Carillon 和 Carillon Mitral Contour System 是 Cardiac Dimensions 的注册商标。

¹ https://pmc.ncbi.nlm.nih.gov/articles/PMC10398425/

¹ https://pmc.ncbi.nlm.nih.gov/articles/PMC10398425/

² https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.122.009689

² https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.122.009689

Contact:

联系人：

Media Contact:

媒体联系人：

PR@cardiacdimensions.com

PR@cardiacdimensions.com